Stockscreener 앱 받기
9.03
1.85%
-0.17
시간 외 거래:
9.00
-0.03
-0.33%
전일 마감가:
$9.20
열려 있는:
$9.22
하루 거래량:
3.71M
Relative Volume:
0.74
시가총액:
$2.29B
수익:
$874.84M
순이익/손실:
$263.86M
주가수익비율:
7.5056
EPS:
1.2031
순현금흐름:
$327.41M
1주 성능:
+1.92%
1개월 성능:
+0.11%
6개월 성능:
+25.94%
1년 성능:
-18.13%
1일 변동 폭
$8.935
$9.305
1주일 범위
$8.81
$9.395
52주 변동 폭
$6.00
$11.31
바이오크리스트 Stock (BCRX) Company Profile
명칭
Biocryst Pharmaceuticals Inc
전화
919-859-1302
주소
4505 EMPEROR BOULEVARD, DURHAM, NC
Compare BCRX vs TAK, ZTS, TEVA, HLN, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
9.03 | 2.34B | 874.84M | 263.86M | 327.41M | 1.2031 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.54 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
572.20 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
바이오크리스트 Stock (BCRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-18 | 재개 | Evercore ISI | Outperform |
| 2025-10-15 | 재개 | TD Cowen | Buy |
| 2025-10-01 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-02-25 | 개시 | Wedbush | Outperform |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-09-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-13 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-02-22 | 업그레이드 | Needham | Hold → Buy |
| 2022-11-02 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2022-08-05 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-08-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-04-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-04-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-12-10 | 개시 | Oppenheimer | Outperform |
| 2021-08-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-08-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-03-01 | 개시 | Cowen | Outperform |
| 2020-09-29 | 재개 | JP Morgan | Overweight |
| 2020-06-17 | 개시 | BTIG Research | Neutral |
| 2020-05-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-11-15 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | 재개 | Piper Jaffray | Overweight |
| 2018-08-08 | 재개 | JP Morgan | Overweight |
| 2018-07-17 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | 개시 | Seaport Global Securities | Neutral |
| 2018-01-02 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | 개시 | Barclays | Equal Weight |
| 2017-09-15 | 개시 | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2017-09-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2017-02-16 | 개시 | Ladenburg Thalmann | Buy |
| 2016-08-12 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 재확인 | FBR Capital | Outperform |
| 2016-02-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2016-02-09 | 다운그레이드 | Needham | Buy → Hold |
모두보기
바이오크리스트 주식(BCRX)의 최신 뉴스
BioCryst Pharmaceuticals earnings loom amid HAE market battle By Investing.com - Investing.com Nigeria
BioCryst Pharmaceuticals earnings loom amid HAE market battle - Investing.com
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
symbol__ Stock Quote Price and Forecast - CNN
BioCryst (BCRX) Secures Licensing Deal for Navenibart in Europe - GuruFocus
BioCryst Pharmaceuticals, Inc. Files Form 8-K with SEC – Company Details, Stock, and Contact Information (May 2026) - Minichart
BioCryst Licenses European Rights to HAE Drug Navenibart - TipRanks
BioCryst licenses navenibart rights in Europe for $70M upfront By Investing.com - Investing.com Canada
BioCryst Pharmaceuticals announced that it has signed a licensing agreement with the Irish subsidiary of Neopharmed Gentili regarding the rights to the hereditary angioedema treatment drug Navenibart in Europe. - Bitget
BioCryst (NASDAQ: BCRX) licenses navenibart in Europe for $70M upfront - Stock Titan
BioCryst lands $70M now, up to $275M more in Europe HAE deal - Stock Titan
BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema - Yahoo Finance UK
Is It Time To Reassess BioCryst Pharmaceuticals (BCRX) After Its Recent Share Price Gains - Yahoo Finance
RBC Capital Raises BioCryst Pharmaceuticals Price Target to 14 Dollars - HarianBasis.co
RBC Capital Lifts PT BioCryst Pharmaceuticals (BCRX) as Part of Q1 2026 Results Preview in Biotech - Insider Monkey
BCRX Should I Buy - Intellectia AI
Vanguard Capital Management (NASDAQ: BCRX) discloses 12.96M-share stake, 5.16% - Stock Titan
5 Best Drug Stocks to Buy According to Analysts - Insider Monkey
BioCryst Pharmaceuticals (BCRX) Projected to Post Earnings on Wednesday - MarketBeat
BCRX Forecast, Price Target & Analyst Ratings | BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX) - ChartMill
BioCryst targets $1B in global ORLADEYO revenue by 2029 amid 33-37% projected growth this year - MSN
BioCryst to Present at Upcoming Investor Conferences - The Manila Times
BioCryst lines up two investor conference presentations in May and June - Stock Titan
Intellia Heads To FDA With Positive Phase III Results For Lonvo-Z - Citeline News & Insights
BioCryst To Acquire Astria Therapeutics In $700M Deal - MSN
MSN Money - MSN
BioCryst appoints Charlie Gayer to succeed Jon Stonehouse as CEO - MSN
BioCryst gains amid takeover speculation - MSN
The Technical Signals Behind (BCRX) That Institutions Follow - Stock Traders Daily
BCRX Price Today: BioCryst Pharmaceuticals Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
[ARS] BIOCRYST PHARMACEUTICALS INC SEC Filing - Stock Titan
BioCryst (BCRX) puts 7M-share incentive plan increase to stockholder vote - Stock Titan
BCRX (BioCryst Pharmaceuticals Inc.) drops 2.38 percent post Q4 2025 EPS miss despite 94 percent year over year revenue growth.Social Flow Trades - Cổng thông tin điện tử tỉnh Tây Ninh
BCRX (BioCryst Pharmaceuticals Inc.) reports steep Q4 2025 EPS miss, stock edges 0.21 percent lower in daily trading.Analyst Ratings - Cổng thông tin điện tử tỉnh Tây Ninh
BCRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
There's No Escaping BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Muted Revenues - 富途牛牛
BCRX Stock Price, Quote & Chart | BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX) - ChartMill
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating - 富途牛牛
Analysts Offer Insights on Healthcare Companies: Harrow Health (HROW) and BioCryst (BCRX) - The Globe and Mail
Phocas Financial Corp. Takes Position in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Is Hiring AI-Focused Rare Disease R&D Leader Sandeep Menon Altering The Investment Case For BioCryst (BCRX)? - Sahm
BioCryst to Report First Quarter 2026 Financial Results on May 6 - Sahm
BioCryst to File Peramivir NDA Supported by BARDA/HHS Funding - AOL.com
Lilly to acquire CrossBridge Bio for up to $300m - Pharmaceutical Technology
BioCryst to Report First Quarter 2026 Financial Results on May 6 | Nation/World | bdtonline.com - Bluefield Daily Telegraph
바이오크리스트 (BCRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.67%
2.13%
자본화:
|
볼륨(24시간):